Lund, Sweden, January 7, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Office ...

Alligator Bioscience AB (publ)’s ("Alligator" or the “Company") rights issue has now been registered with the Swedish Companies ...

Lund, Sweden, December 16, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I ...

Lund, Sweden and Seattle Washington, December 15, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) (NASDAQ: A ...

Alligator Bioscience AB (publ) ("Alligator" or the "Company") has completed the rights issue of ordinary shares (the "Ri ...

Alligator Bioscience AB (publ) ("Alligator" or the "Company") announces that the Company’s rights issue of shares (the “Righ ...

Poster presentation to highlight the ability of ATOR-1017 to activate and rescue tumor infiltrating exhausted T cells in synergy with PD-1 L ...

Poster Presentation to highlight our Neo-X-Prime™ platform that aims to enable antigen presenting cells to efficiently enhance priming of tu ...